<DOC>
	<DOCNO>NCT00133367</DOCNO>
	<brief_summary>The purpose study measure effectiveness 2 drug , tacrolimus sirolimus , prevent graft versus host disease ( GVHD ) treatment chemotherapy follow donor cord blood transplantation .</brief_summary>
	<brief_title>Study Unrelated Cord Blood Transplantation Using Tacrolimus Sirolimus</brief_title>
	<detailed_description>- The chemotherapy portion study involve intravenous administration fludarabine , six day ( Days 8 , 7 , 6 , 5,4 , 3 ) transplant , melphalan , one day ( Day 2 ) transplant . Antithymocyte globulin , thymoglobulin , give IV daily 4 day ( day 7 , 5 , 3 , 1 transplant ) . This drug also help suppress immune system , allow cord blood cell grow reproduce . - Immunosuppression therapy consist drug tacrolimus sirolimus . The patient receive 3 day transplant every day 3-6 month transplant . After first 100 day post transplant , dose tacrolimus sirolimus begin reduce goal patient drug 6-9 month transplant . - After completion conditioning therapy describe , patient receive 2 cord blood unit 1-6 hour apart . To help engraftment , patient also receive G-CSF start day five transplant , patient white blood cell recover . - Follow-up visit continue every 6 month last treatment dose last 2 year . - Blood test draw frequently test whether donor 's immune cell engraft well test level Tacrolimus Sirolimus .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Patients hematologic malignancy allogeneic stem cell transplantation deem clinically appropriate NonHodgkin 's lymphoma , Hodgkin 's lymphoma : Complete Remission &gt; 2 ( second complete remission , third complete remission , etc ) partial remission Multiple myeloma : relapse Chronic lymphocytic leukemia , Rai stage III IV , lymphocyte double time 6 month , stage III , progress &gt; 2 chemotherapy regimen , partial remission . Acute myelogenous lymphoblastic leukemia second subsequent remission first remission adverse cytogenetic antecedent hematologic disorder Chronic myelogenous leukemia accelerate second stable phase , imatinib resistant eligible ablative transplant Myelodysplasia , previously treat eligible ablative transplant Age 1865 year . ECOG performance status 0 , 1 , 2 . Lack 6/6 5/6 HLAmatched relate , 10/10 match unrelated donor , unrelated donor available within time frame necessary perform potentially curative stem cell transplant . Cardiac disease : symptomatic congestive heart failure radionuclide ventriculogram ( RVG ) echocardiogram determine leave ventricular ejection fraction &lt; 40 % , active angina pectoris , uncontrolled hypertension . Pulmonary disease : severe chronic obstructive lung disease , symptomatic restrictive lung disease , correct DLCO &lt; 50 % predict . Renal disease : serum creatinine &gt; 2.0 mg/dl . Hepatic disease : serum bilirubin &gt; 2.0 mg/dl ( except case Gilbert 's syndrome hemolytic anemia bilirubin elevate great 2.0mg/dl ) , SGOT SGPT &gt; 3 x normal . Neurologic disease : symptomatic leukoencephalopathy , active central nervous system ( CNS ) malignancy neuropsychiatric abnormality believe preclude transplantation ( previous CNS malignancy , presently complete remission [ CR ] exclusion ) . HIV antibody . Uncontrolled infection . Pregnancy breast feed mother .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Hematologic malignancy</keyword>
	<keyword>Cord blood transfusion</keyword>
	<keyword>Graft versus host disease</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>sirolimus</keyword>
</DOC>